Johnson & Johnson’s planned separation for its consumer health and personal care products business is full steam ahead but so are the impacts on its results from inflation and COVID-19-related operational disruptions.
A hit to earnings for the global manufacturer and marketer of pharmaceutical, medical devices and consumer health products also is arriving from omitting from its performance forecast sales of its COVID-19 vaccine due to a global surplus and uncertainty about future demand
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?